Creative Commons Attribution LicenseProstate cancer (PC) is the most frequent solid tumor in men and the third most common cause of cancer mortalityamong men in developed countries. Current imaging modalities like ultrasound (US), computerized tomography (CT),magnetic resonance imaging (MRI) and choline based positron emission (PET) tracing have disappointing sensitivity fordetection of nodal metastasis and small tumor recurrence. This poses a diagnostic challenge in staging of intermediateto high risk PC and restaging of patients with biochemical recurrence (PSA >0.2 ng/ml). Gallium-68 labeled prostatespecific membrane antigen (68Ga-PSMA) PET imaging has now emerged with a higher diagnostic yield. 68Ga-PSMAPET/CT or PET/MRI can be expected to offer a one-stop-shop for staging and restaging of PC. PSMA ligands labeledwith alpha and beta emitters have also shown promising therapeutic efficacy for nodal, bone and visceral metastasis.Therefore a PSMA based theranostics approach for detection, staging, treatment, and follow-up of PC would appearto be highly valuable to achieve personalized PC treatment.
Asian Pacific Journal of Cancer Prevention
Zaman, M. u.,
(2017). Diagnostic Challenges in Prostate Cancer and 68Ga-PSMA PET Imaging: A Game Changer?. Asian Pacific Journal of Cancer Prevention, 18(10), 2625-2628.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_radiol/176
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License